Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Blood (2022) 140 (Supplement 1): 397–399.

https://doi.org/10.1182/blood-2022-157988

Published: 2022

Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Blood (2022) 140 (Supplement 1): 10137–10139.

https://doi.org/10.1182/blood-2022-158146

Published: 2022

Journal Articles

Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial

Federico Stella, Vincenzo Marasco, Giorgia Virginia Levati, Cecilia Vismara, Anna Guidetti, Annalisa Chiappella, Giulia Perrone, Cristina Tecchio, Nicola Mordini, Martina Pennisi, Giorgia Ferrara, Giorgia Gobbi, Lucia Saracino, Cristiana Carniti, Paolo Corradini

Blood (2022) 140 (Supplement 1): 417–419.

https://doi.org/10.1182/blood-2022-158662

Published: 2022

Journal Articles

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Anna Guidetti, MD, Giulia Perrone, MD, Paola Coluccia, MD, Luca Fumagalli, MD, Anna Dodero, MD, Lucia Farina, MD, Flavio Arienti, MD, Filippo Bagnoli, MD, Luca Pappalettera, MD, Debora Degli Innocenti, Cristiana Carniti, PhD, Daniela Codazzi, MD, Paolo Corradini

Blood (2019) 134 (Supplement_1): 5619.

https://doi.org/10.1182/blood-2019-125286

Published: 2019

Journal Articles

SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma

Enrica Borsi, Giulia Perrone, MD, Carolina Terragna, PhD, Marina Martello, Manuela Mancini, PhD, Elisa Leo, PhD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2012) 120 (21): 574.

https://doi.org/10.1182/blood.V120.21.574.574

Published: 2012

Journal Articles

The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair

Blood (2012) 120 (21): 1810.

https://doi.org/10.1182/blood.V120.21.1810.1810

Published: 2012

Journal Articles

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Blood (2012) 120 (1): 9–19.

https://doi.org/10.1182/blood-2012-02-408898

Published: 2012

Includes: Supplemental data

Journal Articles

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Elena Zamagni, Francesca Patriarca, Cristina Nanni, Beatrice Zannetti, Emanuela Englaro, Annalisa Pezzi, Paola Tacchetti, Silvia Buttignol, Giulia Perrone, Annamaria Brioli, Lucia Pantani, Carolina Terragna, Francesca Carobolante, Michele Baccarani, Renato Fanin, Stefano Fanti, Michele Cavo

Blood (2011) 118 (23): 5989–5995.

https://doi.org/10.1182/blood-2011-06-361386

Published: 2011

Journal Articles

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

Carolina Terragna, PhD, Marina Martello, Sandra Durante, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Giulia Perrone, MD, Beatrice Anna Zannetti, MD, Enrica Borsi, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2011) 118 (21): 3935.

https://doi.org/10.1182/blood.V118.21.3935.3935

Published: 2011

Journal Articles

HIF 1 Alpha: A Suitable Target for Multiple Myeloma

Giulia Perrone, MD, Enrica Borsi, PhD, Carolina Terragna, PhD, Sandra Durante, Marina Martello, Michela Aluigi, PhD, Manuela Mancini, PhD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Giovanni Martinelli, MD, Maria Alessandra Santucci, MD, Michele Baccarani, MD, Michele Cavo, MD

Blood (2011) 118 (21): 2901.

https://doi.org/10.1182/blood.V118.21.2901.2901

Published: 2011

Journal Articles

Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Blood (2011) 118 (21): 317.

https://doi.org/10.1182/blood.V118.21.317.317

Published: 2011

Journal Articles

Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications

Elena Zamagni, MD, Cristina Nanni, MD, Francesca Patriarca, MD, Annalisa Pezzi, Statistician, Beatrice Anna Zannetti, MD, Paola Tacchetti, MD, Emanuela Englaro, MD, Giulia Perrone, MD, Silvia Buttignol, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Francesca Carobolante, MD, Michele Baccarani, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2011) 118 (21): 826.

https://doi.org/10.1182/blood.V118.21.826.826

Published: 2011

Journal Articles

Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

Blood (2010) 116 (21): 3562.

https://doi.org/10.1182/blood.V116.21.3562.3562

Published: 2010

Journal Articles

Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors

Blood (2010) 116 (21): 620.

https://doi.org/10.1182/blood.V116.21.620.620

Published: 2010

Journal Articles

Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study

Elena Zamagni, Cristina Nanni, Francesca Patriarca, Paola Tacchetti, Emanuela Englaro, Giulia Perrone, Silvia Buttignol, Annamaria Brioli, Lucia Pantani, Beatrice Anna Zannetti, Francesca Caroborante, Michele Baccarani, Stefano Fanti, Michele Cavo

Blood (2010) 116 (21): 369.

https://doi.org/10.1182/blood.V116.21.369.369

Published: 2010

Journal Articles

Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study

Blood (2010) 116 (21): 42.

https://doi.org/10.1182/blood.V116.21.42.42

Published: 2010

Journal Articles

Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis

Blood (2010) 116 (21): 861.

https://doi.org/10.1182/blood.V116.21.861.861

Published: 2010

Journal Articles

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

Güllü Görgün, Elisabetta Calabrese, Ender Soydan, Teru Hideshima, Giulia Perrone, Madhavi Bandi, Diana Cirstea, Loredana Santo, Yiguo Hu, Yu-Tzu Tai, Sabikun Nahar, Naoya Mimura, Claire Fabre, Noopur Raje, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson

Blood (2010) 116 (17): 3227–3237.

https://doi.org/10.1182/blood-2010-04-279893

Published: 2010

Includes: Supplemental data

Journal Articles

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood (2010) 116 (9): 1460–1468.

https://doi.org/10.1182/blood-2009-06-222943

Published: 2010

Includes: Supplemental data

Journal Articles

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Blood (2010) 115 (25): 5202–5213.

https://doi.org/10.1182/blood-2009-12-259523

Published: 2010

Includes: Supplemental data

NARROW

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma

The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

HIF 1 Alpha: A Suitable Target for Multiple Myeloma

Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)

Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications

Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors

Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study

Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study

Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

PI3K/p110δ is a novel therapeutic target in multiple myeloma

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only